429 related articles for article (PubMed ID: 33949933)
21. [Relevant molecular characteristics analysis on malignant transformation of interstitial cells induced by tumor stem cells in glioma microenvironment].
Ji XY; Shi J; Dai XX; Sheng YJ; Xue YP; Liu JC; Cai HH; Dai XL; Chen YM; Zhang YS; Huang Q; Dong J
Zhonghua Yi Xue Za Zhi; 2018 Nov; 98(41):3339-3344. PubMed ID: 30440125
[No Abstract] [Full Text] [Related]
22. Bioinformatic Profiling Identifies a Fatty Acid Metabolism-Related Gene Risk Signature for Malignancy, Prognosis, and Immune Phenotype of Glioma.
Qi Y; Chen D; Lu Q; Yao Y; Ji C
Dis Markers; 2019; 2019():3917040. PubMed ID: 31885736
[TBL] [Abstract][Full Text] [Related]
23. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
24. xCT modulation in gliomas: relevance to energy metabolism and tumor microenvironment normalization.
Savaskan NE; Eyüpoglu IY
Ann Anat; 2010 Sep; 192(5):309-13. PubMed ID: 20801625
[TBL] [Abstract][Full Text] [Related]
25. Extracellular Vesicles As Modulators of Tumor Microenvironment and Disease Progression in Glioma.
Mondal A; Kumari Singh D; Panda S; Shiras A
Front Oncol; 2017; 7():144. PubMed ID: 28730141
[TBL] [Abstract][Full Text] [Related]
26. Glioma initiating cells contribute to malignant transformation of host glial cells during tumor tissue remodeling via PDGF signaling.
Chen Y; Wang Z; Dai X; Fei X; Shen Y; Zhang M; Wang A; Li X; Wang Z; Huang Q; Dong J
Cancer Lett; 2015 Sep; 365(2):174-81. PubMed ID: 26049020
[TBL] [Abstract][Full Text] [Related]
27. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
28. The Acidic Brain-Glycolytic Switch in the Microenvironment of Malignant Glioma.
Reuss AM; Groos D; Buchfelder M; Savaskan N
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073734
[TBL] [Abstract][Full Text] [Related]
29. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
30. Immunological classification of gliomas based on immunogenomic profiling.
Feng Q; Li L; Li M; Wang X
J Neuroinflammation; 2020 Nov; 17(1):360. PubMed ID: 33246490
[TBL] [Abstract][Full Text] [Related]
31. Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells.
Epple LM; Dodd RD; Merz AL; Dechkovskaia AM; Herring M; Winston BA; Lencioni AM; Russell RL; Madsen H; Nega M; Dusto NL; White J; Bigner DD; Nicchitta CV; Serkova NJ; Graner MW
PLoS One; 2013; 8(8):e73267. PubMed ID: 24039668
[TBL] [Abstract][Full Text] [Related]
32. Glioma: molecular signature and crossroads with tumor microenvironment.
Barthel L; Hadamitzky M; Dammann P; Schedlowski M; Sure U; Thakur BK; Hetze S
Cancer Metastasis Rev; 2022 Mar; 41(1):53-75. PubMed ID: 34687436
[TBL] [Abstract][Full Text] [Related]
33. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
Lefranc F; Rynkowski M; DeWitte O; Kiss R
Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
[TBL] [Abstract][Full Text] [Related]
34. Lipid metabolism emerges as a promising target for malignant glioma therapy.
Guo D; Bell EH; Chakravarti A
CNS Oncol; 2013 May; 2(3):289-99. PubMed ID: 24159371
[TBL] [Abstract][Full Text] [Related]
35. Transcriptional Characteristics of
Chang YZ; Li GZ; Pang B; Zhang KN; Zhang XH; Wang YZ; Jiang ZL; Chai RC
Front Cell Dev Biol; 2020; 8():580464. PubMed ID: 33195221
[No Abstract] [Full Text] [Related]
36. The cancer stem cell niche(s): the crosstalk between glioma stem cells and their microenvironment.
Filatova A; Acker T; Garvalov BK
Biochim Biophys Acta; 2013 Feb; 1830(2):2496-508. PubMed ID: 23079585
[TBL] [Abstract][Full Text] [Related]
37. Brain Tumors of Glial Origin.
Waker CA; Lober RM
Adv Exp Med Biol; 2019; 1190():281-297. PubMed ID: 31760651
[TBL] [Abstract][Full Text] [Related]
38. The Critical Role of RNA m
Xu Z; Jiang J; Wang S
Cell Mol Neurobiol; 2023 Jul; 43(5):1697-1718. PubMed ID: 36104608
[TBL] [Abstract][Full Text] [Related]
39. Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Taylor JW; Chi AS; Cahill DP
Oncology (Williston Park); 2013 Jun; 27(6):504-14. PubMed ID: 23909061
[TBL] [Abstract][Full Text] [Related]
40. Malignant gliomas can be converted to non‑proliferating glial cells by treatment with a combination of small molecules.
Oh J; Kim Y; Baek D; Ha Y
Oncol Rep; 2019 Jan; 41(1):361-368. PubMed ID: 30365111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
